Pomerantz LLP is investigating potential securities fraud claims against Disc Medicine, Inc. (IRON) following significant stock price declines. The company's stock fell 7.84% on January 15, 2026 after Reuters reported FDA safety and efficacy concerns about a drug under development. Stock fell further 21.91% on February 13, 2026 when the FDA issued a Complete Response Letter rejecting the New Drug Application for bitopertin, citing insufficient evidence of efficacy.

The Rosen Law Firm announced an investigation into potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following the FDA's issuance of a Complete Response Letter on February 13, 2026, regarding its bitopertin program. The rejection led to a 22% stock price decline. The firm is preparing a class action lawsuit to recover investor losses.

The Portnoy Law Firm has initiated a securities fraud investigation into Disc Medicine, Inc. (NASDAQ: IRON) following a 21.91% stock price decline on February 13, 2026. The collapse was triggered by the FDA's Complete Response Letter rejecting the company's bitopertin drug application for erythropoietic protoporphyria, citing insufficient clinical evidence. The rejection followed earlier regulatory concerns disclosed in January 2025.

Pomerantz LLP is investigating potential securities fraud claims against Disc Medicine, Inc. following significant stock price declines. The company's stock fell 7.84% on January 15, 2026 after Reuters reported FDA safety and efficacy concerns about its drug under development. A subsequent 21.91% drop occurred on February 13, 2026 when the FDA issued a Complete Response Letter rejecting the New Drug Application for bitopertin, citing insufficient evidence of efficacy for treating erythropoietic protoporphyria.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, that rejected the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection triggered a 22% stock price decline, prompting a class action lawsuit to recover investor losses.

Hedge fund BVF invested $52 million in Disc Medicine (IRON) by acquiring 650,000 shares in Q4, demonstrating conviction in the clinical-stage biotech company despite recent FDA setbacks. The investment was made before the FDA's Complete Response Letter in February and a subsequent 20% stock decline. With $791 million in cash runway through 2029, Disc Medicine's investment thesis now hinges on Phase 3 APOLLO trial data expected in Q4 and a potential FDA decision by mid-2027.

The FDA has delayed reviews of several drugs in the Trump administration's fast-track approval program (CNPV) due to safety and efficacy concerns. Disc Medicine's bitopertin for rare blood disorder, Sanofi's Tzield for type 1 diabetes, and Eli Lilly's orforglipron weight-loss pill have all experienced timeline extensions. Regulators cited issues including questionable trial endpoints, adverse events including seizures and deaths, and abuse potential concerns. The delays suggest the one- to two-month review targets may be too aggressive for thorough evaluation.

Disc Medicine reported promising results from its Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis patients, demonstrating substantial hematologic responses across different patient subgroups and transfusion statuses.

Bain Capital Life Sciences Investors completely sold its entire stake in Disc Medicine during Q3 2025, disposing of 583,500 shares worth approximately $30.90 million, signaling a potential shift in institutional sentiment towards the biotech company.

Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.

Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential commercialization of bitopertin and fund research and development.

Disc Medicine received an FDA Commissioner's National Priority Voucher for bitopertin, an investigational drug targeting erythropoietic protoporphyria (EPP), with potential for accelerated approval for patients aged 12 and older.